Q3 2025 Edwards Lifesciences Corp Earnings Call Transcript
Key Points
- Edwards Lifesciences Corp (EW) reported double-digit sales growth of 12.6% in Q3 2025, reaching $1.55 billion.
- The company raised its full-year sales growth guidance to the high end of the previous 9 to 10% range and increased EPS guidance to between $2.56 and $2.62.
- Strong performance was driven by a comprehensive portfolio across multiple therapeutic areas, including aortic, pulmonic, mitral, and tricuspid.
- The Sapien platform has been extensively studied, with over 15 years of clinical trials involving more than 10,000 patients, showcasing excellent durability and clinical outcomes.
- Edwards Lifesciences Corp (EW) maintains a strong and flexible balance sheet with approximately $3 billion in cash and cash equivalents.
- The adjusted gross profit margin decreased to 77.9% from 80.7% in the same period last year, primarily due to foreign exchange and operational expenses.
- Selling, general, and administrative expenses increased to $515 million, or 33.1% of sales, compared to $421 million in the prior year.
- The company anticipates lower second-half operating margin levels compared to the first half due to the timing of key investments.
- There is uncertainty regarding the impact of foreign exchange rates on future margins, with a potential $30 million upside to full-year 2025 sales.
- The CFO, Scott Ullem, announced his transition out of the role by mid-2026, which may lead to leadership changes and potential uncertainties during the transition period.
Greetings and welcome to the Edwards Life Sciences 3rd quarter 2025 conference call.
At this time, all participants are in a listen-only mode.
A question-and-answer session will follow a formal presentation.
If anyone should require operator assistance during the conference, please press 0 on your telephone keypad.
Please note this conference is being recorded.
I will now turn the conference over to your host, Mark Wilterding, senior Vice President, global finance.
Thank you. You may begin.
Thank you, Diego, and thank you everyone for joining us this afternoon. With me on today's call is our CEO Bernard Zavvigian and our CFO Scott Olum. Also joining us for the Q&A portion of the call will be Dan Lippus, our global leader of Taver, and Devien Choprara, who has global responsibility for TMTT and surgical.
Just after the close of regular trading, Edwards Life Sciences released 3rd quarter 2025
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
